Ministry of health of BLR registered new drug AVOPROST, manufactured by Minskintercaps U.V.
Minskintercaps U.V. designed and launched the production of medicine Avoprost, capsules 0.5 mg (INN Dutasterid).
Avoprost is a new modern inhibitor of 5-alfa-reductase for effective cure of benign prostatic hyperplasia.
Indications for usage of Avoprost:
- moderate and severe symptoms of benign prostatic hyperplasia (BPH);
- reducing the risk of acute urine retention and the need of surgical treatment in patients with moderate and severe symptoms of BPH.
Prospective open randomized crossover comparative study of pharmacokinetics and bioequivalence of the drug Avoprost, capsules 0.5 mg, confirmed its bioequivalence with the original drug Avodart®, capsules 0.5 mg.
The drug Avoprost has been available for sale since October 2021.